Patient’s ID/ pos. CDC-CM (n) CDC-CM (Score) ELISA-CM Antibody Detection/ Specific. (PRA max.) PBL T-cell B-cell Class I Class II I.A. (8) 4 2/4 6/8 neg. neg. (PRA = 0%) G.T. (6) 4 2/4 6 neg. neg. (PRA = 0%) K.S. (4) # 4 2 6 neg. neg. (PRA = 22%)§ B.M. (9) 2 1 6 neg. neg. (PRA = 0%) B.S. (4) 2 1/2 6 neg. neg. (PRA = 0%) M.I. (3) # 2/4 1/2 6 neg. neg. (PRA = 0%) R.G. (4) 2 1/2 6 neg. neg. (PRA = 34%)§ P.H. (2) $ 2 1 2/4 neg. neg. (PRA = 55%) K.L. (3) ∞ 2 1/2 4 neg. neg. (PRA = 0%) R.M. (6) 2/4 2 4/6 neg. neg. (PRA = 0%) H.J. (2) # 1/2 1 6/8 neg. neg. (PRA = 0%) H.K. (2) $ 1/2 1 2/4 neg. neg. (PRA = 0%) E.U. (4) + 4/6 4 8 neg. neg. (PRA = 0%) M.I. (8) 4 2 6/8 neg. neg. (PRA = 0%) K.S. (4) ∞ 2 2 4 neg. neg. (PRA = 0%)

Table 2: SLE patients exhibiting various numbers of positive CDC-based crossmatch outcomes (n) during emergency duties with the score-values of the last one shown. Additional ELISA-based crossmatch results performed in parallel and corresponding solid phase-based anti-HLA antibody specification analyses (without CDC-based cell tray analyses) are presented. #: patients were finally allografted by living kidney donations; §: no donor-specific antibodies were identifiable using the Luminex– or DynaChip specification assays in spite of general pre-immunization (PRA); $: faintly positive reaction of B-cells was ignored due to a full house kidney offer (HLA A-B-DR–mismatch: 0-0-0) and the known underlying disease. Retrospectively performed ELISA-based cross-matching wasdefinitely negative; +: living kidney donation projected; ∞: patients were transplanted after the acute attack of the underlying SLE had passed and historical sera identified as false positive had been sorted out